Compounds, compositions and methods

Patent metadata

Field	Value
Publication number	US-12264133-B2
Application number	US-202117452025-A
Country	US
Kind code	B2
Filing date	Oct 22, 2021
Priority date	Jun 17, 2004
Publication date	Apr 1, 2025
Grant date	Apr 1, 2025

Abstract

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

First claim

What is claimed is:

1. A compound of Formula 1D:

or a pharmaceutically acceptable salt thereof.

2. A compound of Formula 1E:

or a pharmaceutically acceptable salt thereof.

3. A method of preparing the compound of claim 1 , or a pharmaceutically acceptable salt thereof, comprising contacting boc-piperazine and sodium triacetoxylborohydride with a mixture of a compound of Formula 1B:

and a compound of Formula 1C:

4. The method of claim 3 , wherein the mixture of the compound of Formula 1B and the compound of Formula 1C is prepared by step a) contacting 1B with diisobutyllithiumaluminum hydride to yield a reaction solution; and step b) admixing the reaction solution with ice and glacial acetic acid.

5. The method of claim 3 , wherein the mixture of the compound of Formula 1B and the compound of Formula 1C is a 20:80 mixture.

6. The method of claim 3 , wherein the contacting is performed in a mixture of HOAc and DCM.

7. The method of claim 4 , wherein step a) is performed in dry Et 2 O at a temperature of about 0° C.

8. A method of preparing the compound of claim 2 , or a pharmaceutically acceptable salt thereof, comprising reducing a compound of Formula 1D:

in the presence of 10% Pd/C in MeOH over an atmosphere of H 2 .

9. A compound of Formula 4B:

or a pharmaceutically acceptable salt thereof.

10. A compound of Formula 4C:

or a pharmaceutically acceptable salt thereof.

11. A method of preparing the compound of claim 10 , or a pharmaceutically acceptable salt thereof, comprising reducing a compound of Formula 4B:

in the presence of Pt/C, K 2 CO 3 , and H 2 .

12. The method of claim 11 , wherein the reducing is performed in THF.

13. The method of claim 11 , wherein an internal reaction temperature is ≤30° C.

14. The method of claim 11 , wherein the compound of Formula 4B is prepared by admixing a compound of Formula 4A:

with methyl piperazine-1-carboxylate.

15. The method of claim 14 , wherein the admixing is performed in the presence of DIPEA in DCM.

Assignees

• Cytokinetics Inc
• Cytokinetics Inc

Inventors

• Morgan Bradley Paul
• Muci Alex
• Lu Pu-Ping
• Tochimoto Todd
• Morgans Jr David J
• Kraynack Erica Anne

Classifications

• C07D417/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D417/00

  Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 · CPC title

• C07D513/04

  Ortho-condensed systems · CPC title

• C07D491/04

  Ortho-condensed systems · CPC title

• C07D487/04

  Ortho-condensed systems · CPC title